Stockscreener 앱 받기
4.06
0.49%
-0.02
시간 외 거래:
4.12
0.06
+1.48%
전일 마감가:
$4.08
열려 있는:
$4.1
하루 거래량:
2.43M
Relative Volume:
0.99
시가총액:
$1.23B
수익:
$248.37M
순이익/손실:
$11.74M
주가수익비율:
81.20
EPS:
0.05
순현금흐름:
$18.24M
1주 성능:
+7.98%
1개월 성능:
+5.45%
6개월 성능:
-32.67%
1년 성능:
-30.00%
1일 변동 폭
$4.02
$4.13
1주일 범위
$3.7378
$4.13
52주 변동 폭
$3.51
$7.63
맨카인드 Stock (MNKD) Company Profile
명칭
Mannkind Corp
전화
818-661-5000
주소
1 CASPER STREET, DANBURY, CA
MNKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.06 | 1.24B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
맨카인드 Stock (MNKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-16 | 재개 | H.C. Wainwright | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-10 | 개시 | Wedbush | Outperform |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-12-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-10 | 개시 | Wedbush | Outperform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 개시 | Oppenheimer | Outperform |
| 2019-10-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2018-02-28 | 다운그레이드 | Maxim Group | Hold → Sell |
| 2017-11-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-10 | 개시 | H.C. Wainwright | Buy |
| 2017-10-06 | 재확인 | Maxim Group | Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-05-10 | 재확인 | Piper Jaffray | Underweight |
| 2016-05-10 | 재확인 | RBC Capital Mkts | Underperform |
| 2016-01-06 | 재확인 | Piper Jaffray | Underweight |
| 2016-01-06 | 재확인 | RBC Capital Mkts | Underperform |
| 2015-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | 다운그레이드 | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-05-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 재확인 | MLV & Co | Hold |
| 2015-04-16 | 재확인 | RBC Capital Mkts | Outperform |
모두보기
맨카인드 주식(MNKD)의 최신 뉴스
What drives MannKind Corporation stock priceFree Stock Selection - PrintWeekIndia
MannKind stock price target lowered to $8 at RBC Capital on model updates - Investing.com Canada
MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association - Insider Monkey
What analysts say about MannKind Corporation stockLightning-fast capital gains - jammulinksnews.com
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
MannKind Corporation Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com
MannKind (NASDAQ:MNKD) Upgraded at HC Wainwright - Defense World
Mannkind director Binder sells $296945 in shares By Investing.com - Investing.com India
H.C. Wainwright assumes coverage on MannKind stock with Buy rating - Investing.com
What makes MannKind Corporation stock price move sharplyLow Risk Scalping Alerts - Newser
How MannKind Corporation stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
Why MannKind Corporation stock attracts strong analyst attentionGrowth Stock Monitor - Newser
High Growth Tech Stocks To Watch In The US July 2025 - Yahoo Finance
Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT - Insider Monkey
13 Best Healthcare Stocks to Buy Under $10 - Insider Monkey
Wedbush Remains Bullish on MannKind Corporation (MNKD) - Insider Monkey
13 Stocks Under $5 With High Upside Potential - Insider Monkey
MannKind Corp stock hits 52-week low at $3.63 - Investing.com
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell 3000 Value Index - MarketScreener
Today In SCV History: June 27, 2014 – Valencia Company Given FDA Approval For Inhaled Insulin - KHTS Radio
Is Day One Biopharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - Insider Monkey
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
MannKind stock hits 52-week low at $3.70 - Investing.com
Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga
Top 3 Oversold Healthcare Stocks to Watch for Rocket-Like Growth - AInvest
Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus
MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com South Africa
MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia
Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech
MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com Nigeria
MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada
MannKind to present inhaled insulin study at ADA event - Investing.com
Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation - Investing.com Australia
MannKind To Present At Jefferies Global Healthcare Conference; Webcast At 2:35 PM ET - Nasdaq
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha
Mannkind Corp (MNKD) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
MannKind stock touches 52-week low at $4.34 amid market shifts - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation - Investing.com
맨카인드 (MNKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):